Abstract
There seems to be an association between exposure to intravenous gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF), a debilitating and sometimes fatal disease. This article addresses the relationship between GBCAs and NSF and answers some common questions. The policy deployed at Yale-New Haven Hospital for prevention of NSF and screening for patients at risk is delineated and discussed along with recommendations by the Food and Drug Administration.
Original language | English (US) |
---|---|
Pages (from-to) | 159-167 |
Number of pages | 9 |
Journal | Magnetic resonance imaging clinics of North America |
Volume | 17 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2009 |
Keywords
- Gadolinium
- Gadolinium chelates
- Gadolinium-based contrast agent
- MR contrast agents
- MR imaging
- Nephrogenic systemic fibrosis
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging